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Anthracycline–trastuzumab-containing regimens demonstrate significant clinical activity in human epidermal
growth factor receptor 2 (HER2)-positive breast cancer; however, the utility of this strategy is limited by
unacceptably high rates of significant cardiotoxicity, particularly with concurrent administration. Anthracycline-
induced cardiotoxicity is thought to be mediated primarily through increased myocardial oxidative stress, modified
partly by the activity of neuregulins. Trastuzumab-induced cardiotoxicity is thought to be mediated by the ErbB/
neuregulin system, with exposure to trastuzumab partly blocking the protective effect of neuregulins on the
myocardium. As a result, trastuzumab increases the risk of anthracycline-induced cardiotoxicity. Several strategies
have been adopted in attempts to minimize cardiotoxicity, including patient selection on the basis of preexisting
cardiac risk, monitoring of cardiac function during treatment, and early management of cardiac dysfunction. The
use of less cardiotoxic anthracyclines may be one strategy to lessen the risk of cardiotoxicity. Liposomal
doxorubicin products offer similar efficacy compared with conventional doxorubicin, with significantly less
cardiotoxicity, and have been successfully used in combination with trastuzumab in the metastatic and neo-
adjuvant setting. Clinical trials are currently underway to assess the safety of pegylated liposomal doxorubicin
during concurrent administration with trastuzumab compared with standard sequential treatment using
conventional doxorubicin in the adjuvant setting.
Key words: adjuvant therapy, anthracyclines, breast cancer, cardiotoxicity, HER2+, pegylated liposomal
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introduction
HER2 is a proto-oncogene and member of the ErbB family of
transmembrane tyrosine kinases. Approximately 15%–25% of
patients with breast cancer have tumors that overexpress the
HER2 protein or amplify the HER2/neu gene. These HER2-
positive tumors are associated with a more aggressive clinical
course compared with HER2-negative tumors [1, 2].
Current adjuvant treatment for HER2-positive tumors is
centered on use of the anti-HER2 mAb trastuzumab, either
concurrent with or sequential to systemic chemotherapy. The
addition of trastuzumab to standard adjuvant chemotherapy yields
significant improvements in both disease-free survival (DFS) and
overall survival (OS) compared with chemotherapy alone [3–6].
Most of the published data support the preferential use of an
anthracycline-containing adjuvant regimen for individuals with
HER2-positive tumors [7–9]. Concurrent anthracyclines and
trastuzumab, however, are contraindicated due to the
observation of unacceptably high rates of cardiotoxicity in
a large randomized trial in the metastatic setting [10]. Due to
this, and despite the observed clinical efficacy of concurrent
anthracycline–trastuzumab therapy, all large adjuvant trials
have evaluated only the sequential strategy of administering
anthracyclines and trastuzumab.
Cardiotoxicity remains an important clinical issue even with
sequential therapy, and strategies to minimize this toxicity have
been proposed [11]. An adjuvant anthracycline–trastuzumab
regimen with less cardiotoxicity, potentially allowing for
concurrent administration, is an area of clinical relevance and
potential value for patients with HER2-positive breast cancer.
This review article will present the rationale for concurrent
anthracycline–trastuzumab therapy, review available clinical
efficacy and cardiac safety data, outline the mechanisms of
cardiotoxicity related to both agents, and review potential
strategies for minimizing cardiac risk with concurrent
anthracycline and trastuzumab treatment regimens.
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rationale for adjuvant anthracycline–
trastuzumab regimens for HER2-
positive disease
Before the introduction of HER2-targeted therapy, HER2-
positive breast cancer was treated with protocols similar to
those employed for HER2-negative tumors. The development
of the anti-HER2 mAb trastuzumab led to clinical trials of
trastuzumab in combination with systemic chemotherapy for
the treatment of HER2-positive metastatic breast cancer
(MBC).
The selection of systemic chemotherapy for use in
combination with trastuzumab was on the basis of preclinical
data demonstrating enhanced antitumor activity when
trastuzumab was combined with doxorubicin or with the
taxane, paclitaxel [12–14]. These preclinical data were
confirmed in the pivotal phase III trastuzumab study involving
women with HER2-positive MBC randomized to treatment
with standard chemotherapy alone or standard chemotherapy
plus concurrent trastuzumab [10]. Anthracycline-naive women
received doxorubicin plus cyclophosphamide (AC) with or
without trastuzumab (H). Women with prior exposure to
anthracyclines received paclitaxel (T) with or without
trastuzumab. The addition of trastuzumab to either the
anthracycline- or taxane-based regimen led to a significant
improvement in overall response rate (50% versus 32%;
P < 0.001) and OS (25 versus 20 months; P = 0.046) compared
with the same chemotherapy alone. Although difficult to
compare directly due to more favorable baseline characteristics,
results in the anthracycline group were numerically superior to
those observed in the taxane group, with an objective
response rate of 42% for AC alone and 56% for AC–H, versus
17% for T alone and 41% for TH. Despite demonstrable disease
activity, however, the utility of concurrent trastuzumab–
anthracycline combinations was obviated by unacceptably high
rates of New York Heart Association (NYHA) class III/IV
cardiotoxicity (16%). The taxane–trastuzumab combination
was also associated with an increased incidence of class III/IV
cardiotoxicity, but at a lower rate (2%) [10, 15].
Data indicating that patients with HER2-positive tumors
may derive preferential benefit from anthracyclines in the
adjuvant setting come from multiple clinical trials. One of the
earliest reports examining this issue, the National Surgical
Adjuvant Breast and Bowel Project (NSABP) protocol B-11,
involved patients with lymph node-positive, hormone receptor-
negative breast cancer randomized to treatment with melphalan
plus fluorouracil with or without doxorubicin. In
a retrospective analysis, patients with HER2-positive tumors
had improved DFS (relative risk (RR) = 0.60; P = 0.001), OS
(RR = 0.66; P = 0.01), relapse-free survival (RFS; RR = 0.58; P =
0.002), and distant DFS (RR = 0.61; P = 0.003) when treated
with the doxorubicin-containing regimen. There was no benefit
to the addition of doxorubicin in the HER2-negative subset [7].
The relationship between HER2 status and responsiveness to
adjuvant anthracycline-containing therapy was evaluated in
premenopausal women with node-positive breast cancer
enrolled in the MA-5 trial led by the National Cancer Institute
of Canada. In this study, patients were randomly assigned to
treatment with cyclophosphamide, epirubicin, and fluorouracil
(CEF) or classic cyclophosphamide, methotrexate,
5-fluorouracil (CMF). At median follow-up times of 5 and
10 years, outcomes were superior for those receiving CEF
[16, 17]. In a recent report, tumor specimens from these trials
were analyzed for HER2 status. For those with HER2-positive
tumors, CEF was superior to CMF, with hazard ratios (HRs)
of 0.52 (P = 0.003) and 0.65 (P = 0.06) for RFS and OS,
respectively. There was no observed difference between CEF
and CMF in patients with HER2-negative disease [9]. In
a separate analysis, topoisomerase II alpha protein
overexpression also predicted for improved DFS and OS in
patients treated with CEF versus CMF [18].
A pooled analysis of the interaction between HER2 status and
benefit of adjuvant chemotherapy as a function of whether or
not an anthracycline was administered as part of an adjuvant
regimen included eight large randomized controlled clinical
trials that examined this issue, two of which were summarized
above. The HR for DFS was 0.71 [95% confidence interval
(CI) 0.61–0.83; P = 0.001) and for OS was 0.73 (95% CI
0.62–0.85; P < 0.001) favoring the inclusion of anthracyclines
for HER2-positive disease. No significant benefit was observed
for anthracycline inclusion for HER2-negative disease with
a HR for DFS of 1.0 (95% CI 0.9–1.11; P = NS) and for OS
of 1.03 (95% CI 0.92–1.16; P = NS). The test for interaction
between HER2 status and receipt of anthracyclines was
significant for both DFS (v2 = 13.7; P < 0.001) and OS
(v2 = 12.6; P < 0.001) [19].
adjuvant doxorubicin/
trastuzumab—clinical data
Data from randomized controlled trials in HER2-positive
disease provide clear evidence of a DFS and OS benefit when
trastuzumab is added to standard chemotherapy in the
adjuvant setting (Table 1) [3–5, 20]. Cardiac safety was an
important aspect of all the trials. Criteria for the definition of
a cardiac event differed among trials but concurrent
trastuzumab–chemotherapy strategies consistently led to higher
event rates compared with strategies where trastuzumab was
administered after completion of chemotherapy (e.g., as in
the HERA trial) [3–5, 20–22]. Due to unacceptably high rates of
cardiotoxicity observed in the metastatic setting as discussed
previously [15], all concurrent strategies avoid administration
of trastuzumab during the anthracycline treatment period.
More recently, data from two adjuvant trials have led to
controversy regarding the superiority of anthracyclines in
HER2-positive disease. In a phase III study, adjuvant docetaxel
plus cyclophosphamide (TC) was associated with an
improved DFS and OS compared with AC. HER2 status was
only assessed in a minority of patients and interaction with
treatment was not significant [23, 24].
Breast Cancer International Research Group (BCIRG) study
006 compared AC–docetaxel (T), AC–TH, and T plus
carboplatin plus H (TCH) in women with HER2-positive
breast cancer (Table 1). At the second interim analysis, there
were no statistically significant differences in DFS and OS rates
between the two trastuzumab-containing regimens (AC–TH
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and TCH; DFS 83% versus 82%; OS 92 versus 91%,
respectively). Both trastuzumab-containing regimens led to
improved DFS and OS rates compared with the
nontrastuzumab-containing regimen. Grade III/IV congestive
heart failure (CHF) was significantly more common with
AC–TH compared with TCH (P = 0.0015) [5], thus
emphasizing the importance of maximizing cardiac safety for
anthracycline–trastuzumab regimens in the adjuvant setting.
The BCIRG 006 trial joins the MA.5 trial and others in which
an association between topoisomerase II–HER2/neu
coamplification and anthracycline benefit has been
demonstrated [25–28]. A systematic review of data from
published, randomized, controlled trials conducted in the
adjuvant setting and reporting HER2 status showed an
incremental efficacy benefit for anthracycline-based therapies
only when HER2 and topoisomerase II are coamplified [29]. In
BCIRG 006, 35% of patients had topoisomerase II–HER2
coamplification. Results from the second interim analysis of
this trial demonstrated that, in the coamplified population,
DFS was not statistically significantly different among the three
arms (AC–T, AC–TH, and TCH). Conversely, in the non-
coamplified population, DFS was significantly poorer in the
AC–T arm compared with AC–TH (P < 0.001) and TCH
(P < 0.001) [5]. These results indicate that the anthracycline
benefit was lost in patients with non-coamplified tumors and
has created an as yet unresolved controversy about the role
of anthracyclines and the potential utility of the TCH regimen
in the treatment of breast cancer.
cardiac safety of doxorubicin
cardiotoxicity rates with conventional doxorubicin
Comparisons of anthracycline-induced cardiotoxicity rates
between studies are problematic due to inconsistencies in
patient populations, treatment regimens, definitions of cardiac
toxic effects, and cardiac assessment tools. However, available
data clearly demonstrate an important risk of cardiotoxicity
in patients treated in either the adjuvant or metastatic setting
with conventional anthracyclines alone or in combination
with standard chemotherapy or trastuzumab.
doxorubicin monotherapy. In a retrospective analysis of 630
patients with MBC or advanced small-cell lung cancer treated
with single-agent doxorubicin, the estimated cumulative
percentage with symptomatic CHF was 5% at a cumulative
dose of 400 mg/m2, 16% at 500 mg/m2, and 26% at 550 mg/m2.
When all cardiac events were considered [defined as (i) ‡20
point left ventricular ejection fraction (LVEF) decline from
baseline; (ii) 10-point LVEF decline from baseline to below
the institution’s lower limit of normal (LLN); (iii) LVEF
decline ‡5 points to below the institution’s LLN; or (iv)
symptomatic CHF on study], the estimated cumulative
incidence was 7% at a lifetime doxorubicin dose of 150 mg/m2,
9% at 250 mg/m2, 18% at 350 mg/m2, 38% at 450 mg/m2, and
65% at 550 mg/m2 [30].
AC therapy. Adjuvant AC is also associated with decreases in
LVEF. After a cumulative doxorubicin dose of 240 mg/m2
administered within the AC regimen in NCCTG N9831, 17% ofT
a
b
le
1
.
P
h
as
e
II
I
tr
ia
ls
o
f
ad
ju
va
n
t
tr
as
tu
zu
m
ab
p
lu
s
an
th
ra
cy
cl
in
es
T
ri
al
(l
as
t
fo
ll
o
w
-u
p
)
R
eg
im
en
a
N
E
ffi
ca
cy
C
ar
d
ia
c
ev
en
ts
D
F
S
O
S
Se
ve
re
C
H
F
Sy
st
o
li
c
d
ys
fu
n
ct
io
n
T
ra
st
u
zu
m
ab
d
is
co
n
ti
n
u
at
io
n
%
H
R
ve
rs
u
s
co
n
tr
o
l
(P
va
lu
e)
%
H
R
ve
rs
u
s
co
n
tr
o
l
(P
va
lu
e)
H
E
R
A
(2
4
m
o
n
th
s)
[3
,
20
,
21
]
A
n
y
C
tx
b
16
93
74
–
90
–
0
0.
5%
c
A
n
y
C
tx
b
/
H
16
94
81
0.
64
(0
.0
00
1)
92
0.
66
(0
.0
11
5)
0.
6%
3.
0%
c
4.
3%
N
C
C
T
G
N
98
31
an
d
N
SA
B
P
B
-3
1
(2
4
m
o
n
th
s)
[4
,
22
]
A
C
/
T
16
79
67
–
91
–
0.
8%
d
17
%
e
–
A
C
/
T
H
16
72
85
0.
48
(<
0.
00
01
)
87
0.
67
(0
.0
15
)
4.
1%
d
34
%
e
19
%
B
C
IR
G
-0
06
(s
ec
o
n
d
in
te
ri
m
an
al
ys
is
at
36
m
o
n
th
s)
[5
]
A
C
/
T
10
73
77
–
86
–
0.
4%
10
%
f
–
A
C
/
T
H
10
74
83
0.
61
(<
0.
00
01
)
92
0.
59
(0
.0
04
)
1.
9%
18
.1
%
f
N
o
t
ye
t
p
u
b
li
sh
ed
T
C
H
10
75
82
0.
67
(0
.0
00
3)
91
0.
66
(0
.0
17
)
0.
4%
8.
6%
f
N
o
t
ye
t
p
u
b
li
sh
ed
F
in
H
E
R
(3
6
m
o
n
th
s)
[6
]
T
o
r
V
/
F
E
C
g
11
6
78
–
90
–
4%
3%
e
–
T
o
r
V
+
H
/
F
E
C
+H
g
11
5
89
0.
42
(0
.0
1)
96
0.
41
(0
.0
7)
0
0
N
o
t
re
p
o
rt
ed
a T
h
e
fi
rs
t
re
gi
m
en
sh
o
w
n
fo
r
ea
ch
st
u
d
y
is
th
e
co
n
tr
o
l
re
gi
m
en
.
b
A
p
p
ro
xi
m
at
el
y
94
%
o
f
p
at
ie
n
ts
re
ce
iv
ed
an
th
ra
cy
cl
in
e-
co
n
ta
in
in
g
ch
em
o
th
er
ap
y.
c A
b
so
lu
te
d
ec
li
n
e
o
f
>1
0%
fr
o
m
b
as
el
in
e
an
d
to
<5
0%
,
co
n
fo
rm
at
io
n
af
te
r
3
w
ee
ks
.
d
C
u
m
u
la
ti
ve
in
ci
d
en
ce
.
e A
b
so
lu
te
d
ec
li
n
e
o
f
>1
0%
fr
o
m
b
as
el
in
e
an
d
to
<5
0%
.
f R
el
at
iv
e
d
ec
li
n
e
o
f
L
V
E
F
>1
0%
.
g
Se
co
n
d
ra
n
d
o
m
iz
ed
gr
o
u
p
to
tr
as
tu
zu
m
ab
o
r
n
o
tr
as
tu
zu
m
ab
o
n
ly
in
cl
u
d
ed
th
e
H
E
R
2-
p
o
si
ti
ve
p
at
ie
n
ts
.
A
,
an
th
ra
cy
cl
in
e;
C
,
cy
cl
o
p
h
o
sp
h
am
id
e;
C
tx
,
ch
em
o
th
er
ap
y;
C
H
F
,
co
n
ge
st
iv
e
h
ea
rt
fa
il
u
re
;
H
,
tr
as
tu
zu
m
ab
;
H
R
,
h
az
ar
d
ra
ti
o
;
T
,
ta
xa
n
e;
V
,
vi
n
o
re
lb
in
e.
review Annals of Oncology
1532 | Rayson et al. Volume 19 | No. 9 | September 2008
1536 patients had an asymptomatic LVEF decline ‡10%
but <20% compared with baseline and 7% had an
asymptomatic decline ‡20% to below the LLN [31]. Adjuvant
trials incorporating trastuzumab concurrent with paclitaxel and
following AC have consistently observed that 7% of patients
who complete four cycles of AC experience cardiotoxicity
precluding the subsequent administration of trastuzumab [4,
22]. In addition, several trials have shown that a lower LVEF
before initiation of trastuzumab, as well as increasing age,
increases the risk of treatment-associated contractile
dysfunction [21, 22].
cardiac safety of doxorubicin–trastuzumab
combination therapy
Trastuzumab monotherapy carries a risk of cardiotoxicity when
administered to patients with metastatic disease, with an
incidence of cardiac dysfunction (symptomatic CHF,
cardiomyopathy, or >10 point decrease in LVEF) ranging from
2% to 9% [15, 32, 33]. The risk of trastuzumab-associated
contractile dysfunction appears to be lower in anthracycline-
naive patients [22].
In the anthracycline–trastuzumab arm of the pivotal trial in
HER2-positive MBC, patients were treated for a planned
duration of six cycles (cumulative anthracycline dose
360 mg/m2), with further cycles administered at investigator
discretion. With this, the incidence of cardiac dysfunction and
NYHA classes III–IV cardiotoxicity (i.e., symptomatic CHF)
was 27% and 16%, respectively [10, 15, 34]. Cardiotoxicity
rates were lower in subsequent trials conducted in patients with
MBC after the risk of cardiotoxicity was recognized and
concurrent administration with anthracyclines was avoided. In
an analysis of pooled data from six MBC trials, 11.6% of
patients treated with trastuzumab after prior anthracyclines
experienced a fall in LVEF of ‡15 points to a level <50% [34].
Data on the risk of cardiotoxicity in the adjuvant setting
continue to evolve. Recognition of cardiotoxic risk with
anthracycline–trastuzumab combinations has led to rigorous
cardiac eligibility criteria for adjuvant trastuzumab trials; most
trials now require a normal postanthracycline LVEF before
initiating treatment with trastuzumab. Cardiac safety data from
the individual trials of adjuvant sequential anthracycline–
trastuzumab are shown in Table 1. The cumulative long-term
risk of symptomatic or asymptomatic cardiac dysfunction in
patients treated in these trials is unknown as are the
implications of less severe cardiac toxic effects not meeting the
trial definition of an event [35]. These issues are especially
germane to patients treated in the adjuvant setting as long-term
increases in cardiotoxic risk may counterbalance a portion of
the benefit of successful breast cancer treatment.
The differences in rates of cardiac events and trastuzumab
discontinuations between concurrent and sequential strategies
merits discussion. In an analysis of cardiac dysfunction in
the NSABP B-31 trial carried out at a median follow-up of
27 months, the cumulative incidence of class III/IV CHF 3 years
after initiating treatment with the TH portion of the AC–TH
regimen was 4.1%. In this trial, 19% of women discontinued
trastuzumab treatment for cardiac reasons. Both post-AC LVEF
and older age were found to be important predictors of
cardiotoxicity in this analysis [22, 36]. In the N9831 trial
comparing AC–T chemotherapy alone to the same
chemotherapy plus trastuzumab, either concurrent (with T) or
subsequent to chemotherapy, the incidence of grade III/IV
cardiotoxicity was 2.8% and 3.3% for the trastuzumab-
containing arms (trastuzumab sequential to, versus concurrent
with, paclitaxel) versus 0.3% for the nontrastuzumab arm.
Factors associated with increased risk of cardiac events included
older age, lower baseline LVEF, and prior/current use of
antihypertensive medications [36]. In an analysis of cardiac
dysfunction in the HERA trial carried out at a median follow-
up of 12 months, the rate of severe (class III/IV) CHF in the
trastuzumab arm was 0.6%. Trastuzumab was discontinued for
cardiac reasons in 4.3% of women [21]. A direct comparison
of these trials is complicated by the use of different
methodologies; however, certain differences are of interest.
First, the cardiac eligibility criteria for beginning trastuzumab
were more stringent in HERA where patients were required to
have a LVEF ‡55% [3]. In contrast, the LVEF threshold was
effectively ‡50% in NSABP B-31 as patients were allowed to
receive trastuzumab if their LVEF was above the institution’s
LLN as long as they did not experience a drop in LVEF from the
prechemotherapy value of >15 percentage points [22]. Second,
the amount of time elapsed between the completion of
anthracyclines (received by all patients in NSABP B-31/N9831
and 94% of patients in HERA) and trastuzumab initiation
was longer in the HERA trial. The median time between last
dose of anthracycline and trastuzumab was 89 days in the
HERA trial compared with 21 days in NSABP B-31/N9831
[4, 21, 36]. Thus, it is possible that the longer elapsed time
between administration of the anthracycline and trastuzumab
may result in less oxidative stress to the myocardium,
supporting a potential role for anthracycline-associated
oxidative stress as a risk factor for trastuzumab-related cardiac
dysfunction. As well, a longer elapsed interval may avoid the
blockade of erbB2-driven mechanisms involved in tissue rescue
of acutely injured myocardium as a result of anthracycline
exposure, potentially mitigating observed cardiotoxicity.
Two neo-adjuvant studies incorporating anthracyclines and
trastuzumab have documented significant pathologic
complete response (pCRs) rates in this patient population.
Buzdar et al. [37] have updated their initial cohort, treated
preoperatively with paclitaxel followed by an anthracycline-
based regimen (FEC75; 5-fluorouracil, epirubicin,
cyclophosphamide), to include a final patient sample of 64, of
whom 45 received concurrent chemotherapy plus trastuzumab
for HER2-overexpressing disease. The pCR in this group was
60% (95% CI 44.3% to 74.3%) versus a pCR rate of 26.3%
(95% CI 9% to 51%) in the nontrastuzumab arm. Median
LVEF values in the trastuzumab-receiving cohort declined from
65% at baseline to 60%, with the LVEF median and range
decreasing over time and a 95% CI of the probability of cardiac
failure between 0% and 7.87%. The NOAH trial, published in
abstract form to date [38], randomized a subset of patients
with HER2-positive disease to sequential neo-adjuvant
chemotherapy (AT; doxorubicin–paclitaxel · 3, T; paclitaxel · 3
and CMF; cyclophosphamide, methotrexate, 5-fluorouracil · 3)
either with or without concurrent trastuzumab. Early results
indicate a significant improvement in pCR rates for the
Annals of Oncology review
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trastuzumab-containing arm (pCR 43% versus 23%; P = 0.002)
with cardiotoxicity rates (LVEF decline by 10% or greater,
congestive heart failure) of 15.7% for the trastuzumab regimen
versus 11.5% for the nontrastuzumab arm.
In addition to the analyses just discussed, there has been
a meta-analysis of cardiac effects in >11 000 women enrolled in
adjuvant trials of chemotherapy plus trastuzumab including
the five trials shown in Table 1. When considering only the
arms in which trastuzumab was administered for 1 year,
a significantly increased risk of NYHA class III or IV CHF (RR,
7.05, 95% CI 3.88–12.83; P < 0.0001) was observed with an
absolute difference of 1.61% compared with the
nontrastuzumab-containing treatment arms. The risk of
asymptomatic contractile dysfunction was also significantly
increased (RR, 2.18, 95% CI 1.45–3.27; P = 0.00016). The
absolute OS benefit observed in the trastuzumab-treated cohort
was 1.96% on the basis of relatively short-term follow-up [11].
Both cardiac event rates and absolute OS benefits may
change over time and will need to be more fully elucidated
before a more complete understanding of both the benefits and
risks of anthracycline–trastuzumab-containing adjuvant breast
cancer regimens can be achieved.
mechanisms of cardiotoxicity
Anthracycline-induced cardiotoxicity is a progressive disease
that evolves in a stepwise fashion, with changes in cardiac
ultrastructure occurring in advance of clinical manifestations of
cardiac dysfunction [39]. Depending on dose,
pharmacokinetics, and type of anthracycline used, myocardial
cell loss or functional damage can occur. Initially, only
a relatively modest decline in contractile function may occur
because physiologic mechanisms can compensate for
myocardial cell loss and declines in pump function. Additional
cardiac insult and secondary damage may subsequently, over
time, lead to left ventricular remodeling and symptomatic heart
failure. Compensatory mechanisms include activation of the
neurohumoral pathways (such as the renin-angiotensin and
adrenergic system), myocardial hypertrophy, and possibly
survival factors such as the neuregulin/ErbB system [40–42].
The exact changes that occur during the transition to
symptomatic disease are not yet entirely elucidated [40, 41].
Morphologic myocardial change following anthracycline
treatment includes myocardial cell loss by necrosis or
apoptosis, myofibrillar loss as well as sarcoplasmic reticulum,
and mitochondrial swelling [43]. The major mechanism
underlying these structural changes is anthracycline-induced
oxidative stress with interventions attenuating oxidative stress
being generally cardioprotective [44].
In addition to their expression in certain tumors, ErbB
receptors are expressed in the myocardium where they serve as
receptors for neuregulins. Neuregulins are pivotal for myocyte
survival in the stressed myocardium [45] and it is likely that
trastuzumab-induced cardiotoxicity results from interference
with the action of neuregulin [46]. Thus, the inhibition of
ErbB2 signaling by trastuzumab in patients receiving
doxorubicin may interfere with the protective effects of
neuregulin on the anthracycline-damaged myocardium. This
may account for the increased clinical cardiotoxicity observed
with concurrent and sequential anthracycline–trastuzumab
administration [3–5, 47].
Furthermore, studies conducted in rat cardiocytes
demonstrate that the neuregulin/ErbB system, the target for
trastuzumab, can attenuate anthracycline-induced myocardial
damage [46] by reducing anthracycline-associated oxidative
stress [44]. When myofibrillar structure was assessed in
cultured adult rat ventricular myocytes, doxorubicin induced
a concentration-dependent increase in myofilament disarray
and cell death [46]. This suggests that cardiotoxicity is
increased as myocardial doxorubicin concentration increases,
likely due to higher levels of oxidative stress.
alternative anthracycline-based
strategies
epirubicin
Equipotent epirubicin is considered to be less cardiotoxic than
conventional doxorubicin, with comparative cardiotoxicity
reported to be 1 : 1.8 in favor of epirubicin [48]. The
concurrent administration of epirubicin plus trastuzumab is
being assessed in a multicenter phases I–II trial. The phase I
portion of the study evaluated the cardiac safety of up to six
cycles of epirubicin (E, 60 or 90 mg/m2) and C (600 mg/m2)
with or without H in anthracycline-naive women with MBC.
Those with HER2-positive disease received E60CH (n = 26) or
E90CH (n = 25), with HER2-negative patients receiving E90C
and serving as controls (n = 23). Protocol-defined cardiac
toxicity (>10 point decrease in LVEF to <50%) occurred in
three patients receiving trastuzumab (6%) and in no patients in
the control group. Two patients treated with E90CH
experienced symptomatic CHF and one patient treated with
E60CH experienced an asymptomatic decrease in LVEF to
<50%. Asymptomatic decreases in LVEF >10% but with an
LVEF ‡50% were reported in 48% of patients treated with
E60CH and in 56% treated with E90CH compared with 24% in
the control group [49]. Data from this phase I trial seem to
indicate similar issues regarding additive cardiotoxicity with
concurrent epirubicin–trastuzumab as has been observed with
doxorubicin.
A large retrospective analysis suggests that epirubicin-
associated cardiotoxicity may be more common than
previously thought. Of 1097 anthracycline-naive patients with
MBC treated with epirubicin, 11.4% developed ‡grade II
cardiotoxicity. For every 100 mg/m2 of epirubicin
administered, the risk of cardiotoxicity increased 37%. Risk of
cardiotoxicity developed at a progressively lower cumulative
dose as a function of age (806 mg/m2 at age 40 versus
609 mg/m2 at age 70) [50].
liposomal anthracyclines
Liposomal anthracyclines have been developed in an attempt to
improve the overall safety profile, and in particular the cardiac
safety profile, of conventional anthracyclines. Two liposomal
doxorubicin formulations are available: pegylated liposomal
doxorubicin (PLD; Caelyx, Schering Plough, Kenilworth, NJ;
Doxil, Ortho Biotech, Raritan, NJ) and nonpegylated
liposomal doxorubicin (LD; Myocet; Zeneus Pharma
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Limited, Oxford, UK and Sopherion Therapeutics, Princeton,
NJ). Liposomal daunorubicin (DaunoXome, Diatos, Paris,
France) is available in Europe and Brazil.
Liposome encapsulation alters the safety profile of
anthracyclines by modifying their pharmacokinetics and
biodistribution. Following administration of a liposomal
formulation, most of the doxorubicin in plasma is
encapsulated. Once in the tissue, encapsulated doxorubicin is
released from the liposome. Due to their size (100–180 nm in
diameter), liposomes cannot escape the circulation through the
tight capillary junctions found in normal tissue such as the
heart, but can escape through the weakened vasculature that
feeds tumor cells [51]. Thus, with a liposomal product, the
drug is preferentially directed away from sites of toxicity to the
site of action.
Adverse effects such as acute nausea and vomiting and
cardiotoxicity are thought to be related to peak plasma and
tissue concentrations of free doxorubicin. The rationale for the
observed reduction in nausea, vomiting, and cardiotoxicity
with liposomal formulations compared with conventional
doxorubicin is on the basis of lower plasma and tissue
(particularly myocardial)-free doxorubicin concentrations [52,
53]. Minimization of myocardial exposure to free doxorubicin
induces less myocardial oxidative stress compared with
conventional doxorubicin. This reduction in oxidative stress
should attenuate doxorubicin-induced cardiotoxicity [54, 55].
Conventional liposomal formulations are cleared rapidly
from plasma [52]. Pegylation of the liposome protects the
product from detection by phagocytes, thus increasing the
plasma half-life and allowing for enhanced accumulation in
tumor [56]. Thus, while LD has a half-life of 2–3 h, PLD has
a half-life in excess of 55 h [51].
monotherapy. Clinical data confirm that monotherapy with
liposomal products is associated with similar efficacy and
reduced cardiotoxicity compared with conventional
doxorubicin in women with MBC (Table 2) [57, 58]. In these
monotherapy studies, percentage LVEF decrease from baseline
was correlated with cumulative dose of both conventional
anthracycline and the liposomal product, but the HR for
cardiotoxicity consistently favored the liposomal products [57,
58]. In patients treated with PLD 50 mg/m2 every 4 weeks, there
was a mean decrease from baseline LVEF of 2%–3% and
a median decrease from baseline LVEF of 2.5% (lifetime dose
<450 mg/m2) to 5% (lifetime dose ‡450 mg/m2) (Figure 1). At
cumulative anthracycline doses of 450 mg/m2 or more, there
was a seven-fold greater mean percentage decrease in LVEF
with conventional doxorubicin compared with PLD. There
were no cases of CHF in 254 patients treated with PLD [57]. In
patients treated with LD 75 mg/m2 every 3 weeks, the median
LVEF decrease from baseline ranged from 0 (at a lifetime
dose of 0–99 mg/m2) to 10% (at a lifetime dose ‡700 mg/m2).
There were two cases of CHF in 108 patients treated with
LD [58].
concurrent trastuzumab. Both liposomal doxorubicin products
have been evaluated in combination with trastuzumab in phase
II studies for patients with HER2-positive MBC (Table 3). A
phase I/II study evaluated LD (60 mg/m2 every 3 weeks) plus
trastuzumab in patients with advanced breast cancer, some
with prior exposure to anthracyclines (38%) and trastuzumab
(30%). Among 37 assessable patients, there was one case
each of symptomatic CHF and asymptomatic cardiotoxicity,
both in patients with prior anthracycline exposure. The overall
tumor response rate was 58% (95% CI 41% to 75%) [59].
Table 2. Phase III studies of single-agent nonpeglyated LD or PLD versus conventional doxorubicin as first-line therapy for metastatic breast cancer
Study Treatment N Efficacy Safety
PFS Response
rate
Median
survival
Cardiotoxicitya Other toxic effects
(liposomal versus
conventional)
O’Brien
et al. [57]
PLD 50 mg/m2
every 4 weeks
254 6.9 months,
HR = 1.00
NR NR 4% (no cases of CHF)
HR = 3.16 (P < 0.001)
Alopecia: 20% versus 66%;
nausea: 37% versus 53%;
vomiting: 19% versus 31%;
stomatitis: 22% versus 15%;
mucositis: 23% versus 13%;
neutropenia: 4% versus 10%;
PPE: 48% versus 2%
Doxorubicin
60 mg/m2
every 3 weeks
255 7.8 months NR NR 19%
Harris
et al. [58]
LD 75 mg/m2
every 3 weeks
108 NR 26% 16 months 13% (two cases of CHF)
HR = 3.56 (P = 0.0001)
Alopecia: 81% versus 88%b;
nausea/vomiting:
13% versus 24%c; stomatitis/
mucositis: 9% versus 14%c;
neutropenia: 50% versus 58%d;
PPE: one case with LD
Doxorubicin
75 mg/m2
every 3 weeks
116 NR 26% 20 months
(P = 0.09)
29%
aAt least a 20-point decrease in LVEF from baseline to a value of 50% or greater (i.e., within normal range) or at least a 10-point decrease from baseline to
a value <50% or clinical CHF.
bGrade 2.
cGrade ‡ 3.
dAbsolute neutrophil count <500 cells/ll.
LD, liposomal doxorubicin; NR, not reported; PLD, pegylated liposomal doxorubicin; PPE, palmar-plantar erythrodysesthesia.
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A phase III study (M77035) is currently evaluating the effect
of first-line treatment with paclitaxel, LD, and trastuzumab in
patients with metastatic or locally advanced HER2-positive
breast cancer.
Four studies have evaluated the cardiac effects of PLD
administered concurrently with trastuzumab. A multicenter
phase II study was conducted in 30 patients with
HER2-overexpressing MBC; 13 had prior treatment with
conventional anthracyclines at a mean cumulative dose of 251
mg/m2 of doxorubicin (range 180–288 mg/m2) and 530 mg/m2
epirubicin (range 309–703 mg/m2). Cardiotoxicity was defined
as (i) clinical signs and symptoms of CHF with ‡10 point
decline from baseline in LVEF to a value below the LLN,
(ii) ‡15 point decline from baseline in LVEF in an
asymptomatic patient, or (iii) <10 point decline from baseline
in LVEF in an asymptomatic patient with an absolute value
<45% on multiple-gated acquisition scan. After a mean of
5.5 cycles of PLD (50 mg/m2 every 4 weeks), cardiotoxicity was
detected in three patients (10%), none of whom developed
symptomatic CHF and all of whom had received prior
treatment with anthracyclines. The disease response rate was
52% with an additional 38% experiencing stable disease (failure
to acheive a response or failure to demonstrate progressive
disease following 2 cycles of PLD and trastuzumab) for >6
months for an overall clinical benefit rate of 90%. With median
follow-up of 13.9 months, the median PFS was 12.0 months
and median OS had not been reached [60].
In a second study, concurrent PLD 30 mg/m2 and docetaxel
60 mg/m2 every 3 weeks plus trastuzumab 4 mg/kg the first
week followed by 2 mg/kg weekly thereafter were administered
as first-line therapy to 48 anthracycline- and trastuzumab-naive
patients with HER2-positive MBC. Forty-one patients with
HER2-negative MBC were treated with PLD plus docetaxel at
the same dosage to serve as internal controls for cardiotoxic
end points. There were no significant differences in mean LVEF
reductions between treatment arms. After four and eight
cycles of therapy, LVEF fell a mean of 2.4% and 5.3%,
respectively, in the PLD plus docetaxel arm and 2.0% and 5.3%,
respectively, in the PLD, docetaxel and trastuzumab arm. No
patient in either group developed symptomatic CHF, but 9%
of patients in the control group and 11% in the group receiving
PLD plus docetaxel plus trastuzumab experienced a LVEF
decline ‡20% or a LVEF below the LLN after eight cycles of
therapy. A response rate of 46%, median duration of response
of 16.3 months, and median survival of 28 months were
observed in the HER2-positive arm [61]. Two smaller studies
have also been conducted as detailed in Table 3 [62, 63].
investigation of PLD plus trastuzumab
in adjuvant therapy
On the basis of the previous discussion, if anthracycline-
induced oxidative stress can be minimized by the use of
a liposomal doxorubicin product, the impact of the loss of the
myocardial protective effects of neuregulin that occurs with
concurrent administration of trastuzumab may be reduced and
cardiotoxicity minimized.
Collectively, data from adjuvant and metastatic trials indicate
that substitution of a liposomal product for conventional
anthracyclines in standard chemotherapy regimens may allow
for the safe, concurrent administration of anthracyclines and
trastuzumab in the adjuvant setting. This concept is being
investigated in a randomized phase II multinational trial. The
Breast cancer Adjuvant Caelyx Herceptin (BACH) study will
evaluate the cardiotoxicity of a doxorubicin-based and a PLD-
based adjuvant chemotherapy regimen in 180 women with
operable, node-positive or high-risk node-negative HER2-
positive breast cancer.
Following surgical removal of the tumor, patients will be
randomly assigned in a 1 : 2 ratio to treatment with four cycles
of standard AC followed by weekly paclitaxel and trastuzumab
or four cycles of PLD (35 mg/m2) [64] and cyclophosphamide
(CC), with concurrent weekly trastuzumab followed by
weekly paclitaxel and ongoing trastuzumab. After eight cycles
of chemotherapy, further treatment will continue as per the
standard of care of the institution and at the discretion of the
investigator. Thus, trastuzumab will be expected to continue
for a total of 1 year on the basis of current knowledge gleaned
from prior large adjuvant trastuzumab trials.
The primary objectives are to determine the incidence of
cardiotoxicity (based on ECG and LVEF measurements) and
the percentage of patients unable to receive trastuzumab over
the planned cycles of chemotherapy or for the full duration
of 1 year, due to cardiac dysfunction.
discussion
Trastuzumab–chemotherapy regimens have dramatically
altered the natural history of HER2-positive breast cancer.
However, the long-term prognosis for patients with breast
cancer depends not only on the efficacy of anticancer treatment
but also on the impact of treatment-induced toxic effects.
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Figure 1. Cardiac event rate in patients treated with pegylated liposomal
doxorubicin (PLD) versus conventional doxorubicin. At the same
cumulative anthracycline dose, PLD is associated with a lower rate of
cardiac events (based on multiple-gated acquisition scan) during treatment
than conventional doxorubicin (hazard ratio = 3.16; 95% confidence
interval 1.58–6.31; P < 0.001 for comparison of cumulative anthracycline
dose at the time of first protocol-defined cardiac event). Data from a phase
III study in 509 women receiving first-line treatment. With permission
from O’Brien et al. [57].
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Cardiotoxicity is a particularly important issue given the large
number of women with breast cancer receiving anthracyclines
in the adjuvant setting. While HER2-directed therapy
provides significant clinical benefit for patients with HER2
positive disease, it presents new concerns regarding
cardiotoxicity, particularly when used in conjunction with, or
immediately following anthracycline-based chemotherapy.
Several strategies to reduce anthracycline–trastuzumab-
induced cardiotoxicity have been proposed with key elements
including establishing stringent LVEF criteria for patient
selection, monitoring cardiac function during therapy, and
discontinuing potentially cardiotoxic therapy when
cardiotoxicity arises. Other strategies to impact cardiotoxic risk
may include using a less cardiotoxic anthracycline and
initiating aggressive management of cardiac dysfunction.
At present, the inclusion of anthracyclines in adjuvant
chemotherapy regimens for patients with HER2-positive breast
cancer is controversial, primarily due to the cardiotoxicity
associated with these regimens and the potential efficacy of
alternative, nonanthracycline-containing regimens such as
TCH. Concurrent anthracycline–trastuzumab administration
has not been attempted in the adjuvant setting and it is
therefore unknown whether concurrent strategies might be
more effective than regimens in which trastuzumab is
administered sequentially following completion of the
anthracycline. Strong evidence indicates that anthracycline-
induced increases in myocardial oxidative stress are a major
factor underlying anthracycline-associated cardiotoxicity and
trastuzumab-associated contractile dysfunction. Future trials
incorporating lapatinib, an oral dual tyrosine kinase inhibitor
of EGFR/ErbB1 and HER2/ErbB2, with early reports of
a favorable cardiac safety profile, may expand the range of
strategies for concurrent HER2 blockade with anthracycline
administration [65]. Liposomal anthracyclines may also allow
for greater cardiac safety and results from the adjuvant BACH
study evaluating concurrent PLD, cyclophosphamide, and
trastuzumab may serve to further develop this strategy and
provide insight into the potential benefits of concurrent
anthracycline–trastuzumab use in the adjuvant treatment of
HER2-positive breast cancer.
Table 3. Phase II studies of liposomal doxorubicin formulations plus trastuzumab in MBC
Study Treatment N Efficacy results Safety results
Nonpegylated LD
Theodoulou et al. [59] LD 60 mg/m2 i.v. every 3 weeks
H 4 mg/kg i.v. week 1, then
2 mg/kg i.v. weekly
37 OR: 58%; SD: 16% CHF: one patient; asymptomatic
cardiotoxicity: 1 patient; grade 4
neutropenic fever: 2/203 cycles; grades
3–4 nausea 2/37 patients (5.4%)
PLD
Chia et al. [60] PLD 50 mg/m2 i.v. every 4 weeks;
H 4 mg/kg i.v. week 1, then
2 mg/kg i.v. weekly
30 OR: 52%; SD: 38%;
PFS: 12.0 months
CHF: none; asymptomatic
cardiotoxicity: 3 patients; grade 3
mucositis: 1/30 patients (3%); grade 3
PPE: 9/30 patients (30%); grades 3–4
neutropenia: 8/30 patients (27%)
Wolff et al. [61] HER2-negative patients; PLD
30 mg/m2 i.v. every 3 weeks;
T 60 mg/m2 i.v. every 3 weeks
41 OR: 40%; TTP:
10.5 months
CHF: none; grades 1–2
cardiotoxicity—cycle 8: 9/22 patients
(41%); ‡30 days post-treatment: 1/9
patients (11%)
HER2-positive patients; PLD
30 mg/m2 i.v. every 3 weeks;
T 60 mg/m2 i.v. every 3 weeks;
H 4 mg/kg i.v. week 1, then
2 mg/kg i.v. weekly
48 OR: 46%; TTP:
13.1 months
CHF: none; grades 1–2
cardiotoxicity—cycle 8: 10/18 patients
(56%); ‡30 days post-treatment: 12/18
patients (67%); increased incidence
grades 2–3 PPE in this arm
Stickeler et al. [62] PLD 40 mg/m2 i.v. every 4 weeks;
H 4 mg/kg i.v. week 1, then
2 mg/kg i.v. weekly
15 CB: 42.9%;
OS: 16.2 months
CHF: none; asymptomatic
cardiotoxicity: 3/15 patients (20%)
Andreopoulou et al. [63] PLD 30 mg/m2 i.v. every 3 weeks;
H 4 mg/kg i.v. week 1, then
2 mg/kg i.v. weekly
12 CB: 67% CHF: one patient (grade 3);
asymptomatic cardiotoxicity (grade 2):
3 patients (25%); grade 3 neutropenia:
2/12 patients (17%); grade 3
hypersensitivity: 2/12 patients (17%);
grade 3 mucositis: 1/12 patients (8%);
grade 3 rash: 1/12 patients (8%); grade
3 esophagitis: 1/12 patients (8%)
CB, clinical benefit (i.e., complete response + partial response + SD); CHF, congestive heart failure; H, trastuzumab; LD, liposomal doxorubicin; OR,
objective or overall response; OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; SD, stable disease; T, taxane
(docetaxel); TTP, time to treatment failure.
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